Editas Medicine says that it will be testing CRISPR-based gene editing in people by 2017, according to Technology Review.
At the EmTech conference, CEO Katrine Bosley said the startup — co-founded by the Broad Institute's Feng Zhang — plans to start a clinical trial within two years to test the use of gene editing to treat Leber congenital amaurosis, a rare form of blindness affecting the retina.